Julia Ketzer

发表

Ponatinib Inhibits Polyclonal Drug-Resistant KIT Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (GIST) Patients

J. Fletcher, T. Clackson, M. Heinrich, 2014, Clinical Cancer Research.

Plasma Sequencing for Patients with GIST—Limitations and Opportunities in an Academic Setting

J. Köster, T. Herold, K. Kostbade, 2022, Cancers.

Inhibitors to Overcome Secondary Mutations in the Stem Cell Factor Receptor KIT.

C. Ehrt, O. Koch, F. Giordanetto, 2017, Journal of medicinal chemistry.

Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797S† †Electronic supplementary information (ESI) available. CCDC 1876852. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/c9sc03445e

J. Hengstler, R. Zahedi, L. Kollipara, 2019, Chemical science.

Kovalent‐allosterische Kinase‐Inhibitoren

P. Janning, S. Pelly, Zhizhou Fang, 2015 .

Covalent-Allosteric Kinase Inhibitors.

P. Janning, S. Pelly, W. V. van Otterlo, 2015, Angewandte Chemie.

Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours

J. Fletcher, G. Demetri, C. Raut, 2019, British Journal of Cancer.

Targeting gain of function and resistance mutations in Abl and KIT by hybrid compound design.

Roman K. Thomas, M. Sos, Anu Gupta, 2013, Journal of medicinal chemistry.

Targeting Her2-insYVMA with Covalent Inhibitors - A Focused Compound Screening and Structure-Based Design Approach.

W. V. van Otterlo, D. Rauh, S. Bauer, 2020, Journal of medicinal chemistry.

KIT-Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors — TORC1/2 Inhibition as Salvage Strategy

S. Fröhling, A. Stenzinger, J. Fletcher, 2019, Molecular Cancer Therapeutics.

Indazole-Based Covalent Inhibitors To Target Drug-Resistant Epidermal Growth Factor Receptor.

C. Schultz-Fademrecht, D. Rauh, S. Bauer, 2017, Journal of medicinal chemistry.

Insight into the Inhibition of Drug-Resistant Mutants of the Receptor Tyrosine Kinase EGFR.

R. Zahedi, L. Kollipara, C. Schultz-Fademrecht, 2016, Angewandte Chemie.

Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours

J. Fletcher, G. Demetri, C. Raut, 2019, British Journal of Cancer.

Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours

J. Fletcher, G. Demetri, C. Raut, 2019, British Journal of Cancer.

Evaluation of the Effect of Photodynamic Therapy on CAM-Grown Sarcomas

U. Dirksen, W. Hartmann, J. Hardes, 2023, Bioengineering.

The Vision of Children about Dental Treatment According to the Type of School (Public or Private)

Elisabete Rabaldo Bottan, Julia Ketzer, Ana Luiza Heusi da Rocha, 2012 .

Plasma sequencing to detect a multitude of secondary KIT resistance mutations in metastatic gastrointestinal stromal tumors (GIST).

M. Schuler, T. Herold, F. Breitenbuecher, 2015 .